|Articles|November 2, 2021
- Pharmaceutical Technology, November 2021 Issue
- Volume 45
- Issue 11
ADCC Expression Cell Line
Author(s)Pharmaceutical Technology Editors
The ADCC+ Cell Line is designed for rapid identification of clones expressing high levels of recombinant therapeutic proteins.
PerkinElmer’s antibody-dependent cellular cytotoxicity (ADCC)+ Cell Line is an expression cell line for the company’s Horizon Discovery CHOSOURCE platform, which is designed for rapid identification of clones expressing high levels of recombinant therapeutic proteins.
The ADCC+ cell line eliminates the fucose gene to increase ADCC activity with the intent of improving the potency and efficacy of therapeutic antibodies and fusion protein biotherapeutics. At the same time, it aims to reduce dosage requirements and side effects for patients.
Articles in this issue
about 4 years ago
The Earlier the Better for Formulation Strategiesabout 4 years ago
Taking an Alternative Approach to Drug Deliveryabout 4 years ago
Visual Inspection: Seeing Room for Improvement?about 4 years ago
Detecting and Determining Quantitation Limits for Impuritiesabout 4 years ago
Labeling Efficientlyabout 4 years ago
Meeting Supply and Training Challengesabout 4 years ago
Pandemic Alters FDA Inspections and Quality OversightNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Audits, Inspections, and CDMOs
2
Ready or Not: Biopharma Alignment for CNPV’s Rapid Review
3
Molecular Dynamics and Quantum Calculations: AAPS Thermo Fisher Interview, Part Two
4
FAQ: Everything to Know About Excipients in the Digital Era
5
